News | January 24, 2017 | ASCO 2017 Gastrointestinal Cancers Symposium.
Nivolumab [immunotherapy] New Standard for Previously Treated MSI-H Metastatic CRC.
"The immune checkpoint inhibitor nivolumab showed durable responses and disease control in a group of heavily pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer, according to updated results from the CheckMate 142 study (abstract 519) [...]
"“Nivolumab monotherapy provided durable responses, disease control, and long-term survival in patients with MSI-H metastatic CRC,” said Michael J. Overman, MD, of the University of Texas MD Anderson Cancer Center. “Responses were observed regardless of tumor or immune cell PD-L1 expression, regardless of BRAF or KRAS mutation status, and regardless of clinical history of Lynch syndrome.”
"[...] about 4% of patients with metastatic colorectal cancer have a high degree of microsatellite instability due to a deficiency in the DNA mismatch repair system. These patients may be less responsive to conventional chemotherapy than patients who are mismatch repair proficient, and their disease is associated with elevated levels of tumor neoantigens, and tumor-infiltrating lymphocytes, and have upregulated expression of checkpoint regulators in immune cells.
"“These results suggest that nivolumab should be considered a new standard of care for patients with previously treated MSI-H advanced CRC,” Overman said. “This is in line with the recent amendment to NCCN guidelines which recommend all metastatic colorectal cancer patients have testing for MSI-H and also patients with MSI-H colorectal cancer after initial therapy be considered for either pembrolizumab or nivolumab monotherapy.”"
More: http://www.cancernetwork.com/asco-2017- ... static-crc
MS= MicroSatellite
MSS = MicroSatellite Stable (or also "repair PROeficient)
MSI = MicroSatellite Instable (or also "repair DEeficient) MSI-H = microsatellite instable High,